PALO ALTO, Calif., Jan. 2, 2018 /PRNewswire/ -- CTIC Capital today announced that Randy, W. Schekman, Nobel laureate, the 2013 Nobel Prize in Physiology or Medicine, Professor of Molecular and Cell Biology, University of California, Berkeley, will serve as the keynote for its second annual CTIC Capital Cross-Border Healthcare Investment Summit, co-hosted by BioCentury. Convening more than 150 Chinese healthcare investors, the Summit will be held on Sunday, January 7, 2018, at the Hyatt Regency San Francisco. Dr. Schekman's presentation is entitled, "Prospects for Use of Exosomes in Cancer Diagnosis and Treatment." http://www.cticcapital.com/2018-healthcare-investment-summit/
"The 2018 CTIC Capital Cross-Border Healthcare Investment Summit serves as the definitive place for Chinese and US investors and executives to network, collaborate and build partnerships," said Yanhong Lin, Founder and Managing Partner, CTIC Capital. "Building on the tremendous success of last year's inaugural Summit which was the most well-attended event during the JP Morgan Healthcare Conference by top Chinese investors, this year's conference has attracted the top Chinese healthcare investment firms and pharmaceutical companies, and our Chinese investment speakers are the most sought-after investors in China. Our agenda is jam-packed and we couldn't be more thrilled."
Attendees at the event will participate in motivating keynote and panel discussions from an impressive array of speakers, partnering opportunities with a 1:1 ratio between investors and company executives, and startup competitions. New features of this year's Summit include:
- Extended time for one-on-one partnering systems mobile app that facilitates communications between investors and company executives
- Each of the six companies out of hundreds of applications will present and be evaluated by one investor with the goal of providing insights into the industries and elements to be a successful investment project from Chinese investors' perspective
"The US is the most innovative country for healthcare technologies and I am most excited about the opportunity to meet company executives and potential partners at CTIC Capital's event," commented Xiaobao Lu, Partner, Sequoia Capital China.
Partial confirmed participating investors include: 3E Bioventures, AbbVie, Ally Bridge Group, Bayer, Berry Genomics, BioSciKin, Button Capital, Canaan, CD Capital, CDH Venture, CLI Ventures, Cloudstone Ventures, CRV, Cybernaut Investment Group, daVinci Capital Group, Decheng Capital, Delos Capital, Dian Diagnostics, DigitalDx Ventures, Flagship Pioneering, Fosun Healthcare Holdings, Fosun Pharma, FountainVest Partners, Foxconn Healthcare Group, GF Investments, GF Xinde Investment Company, Good Health Capital, Hemi Ventures, Hermed Capital, Hopu Capital, IDGVC, InterWest Partners, Khosla Ventures, KPCB China, LDV Partners, Legend Capital, Life Science Angels (LSA), Lilly Asia Ventures, Lumira Capital, Lyfe Capital, Marathon venture partners, Milestone Capital, Morningside Ventures, Northern Light Venture Capital, Ping An Bank, Ping An Ventures, Qilu Pharmaceuticals, Qiming Venture, Sangel Capital, SANOFI, SanPower Group, Sequoia Capital China, Shanghai Jianxin Capital Management, Silicon Valley Future Capital, Teng Yue Partners, Tianjin Ren Ai Group, Top Tier Capital Partners, Virtus Inspire Ventures, VMS Investment Group, Wondfo, YF Capital, Yimei Capital, Zhejiang Grand Health Industry Equity Investment Fund.
Event sponsors include:
Converge Minds, H. C. Wainwright & Co., Wilson Sonsini Goodrich & Rosati, Sequoia Capital China, East West Bank, PitchBook, LYFE Capital, Sangel Capital, Moss Adams, and China-US Program for Entrepreneurship and Innovation.
About CTIC Capital
CTIC Capital is a Silicon Valley based boutique private equity consulting firm focusing on healthcare, Internet technology and alternative energy. Leveraging our trans-pacific network and local expertise, we help US and Chinese enterprises in funding, M&A and strategic partnership development. Our goal is to be the trusted partner for US and Chinese enterprises in their cross-border investments and business expansion. Visit www.cticcapital.com for more information.
SOURCE CTIC Capital